Dec 10, 2019 8:30am EST Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform
Dec 09, 2019 8:30am EST Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
Oct 30, 2019 8:30am EDT Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
Oct 15, 2019 8:35am EDT Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
Oct 15, 2019 8:30am EDT Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
Oct 03, 2019 8:30am EDT Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting